Segment Information - Schedule of Segment Information (Details) - USD ($)	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Net Loss	$ (10,092,363)	$ (11,818,652)
Total operating costs and expenses	9,978,202	12,140,005
Less non-cash share-based compensation	(4,137,460)	(5,713,746)
Operating costs and expenses excluding non-cash share-based compensation	5,840,742	6,426,259
Total assets	9,452,964	6,293,693
CAR-T Therapeutics [Member]
Net Loss	(2,241,443)	(5,074,868)
Operating costs and expenses excluding non-cash share-based compensation	1,141,542	2,212,090
Total assets	2,988,124	2,382,460
Cancer Vaccines [Member]
Net Loss	(828,136)	(677,450)
Operating costs and expenses excluding non-cash share-based compensation	365,681	458,392
Total assets	946,923	489,881
Anti-Viral Therapeutics [Member]
Net Loss	(1,168,969)
Operating costs and expenses excluding non-cash share-based compensation	739,140
Total assets	2,464,361
Cancer Diagnostics [Member]
Net Loss	(5,836,594)	(5,196,471)
Operating costs and expenses excluding non-cash share-based compensation	3,581,377	2,689,761
Total assets	2,869,529	2,921,784
Patent Licensing [Member]
Net Loss	(17,221)	(869,863)
Operating costs and expenses excluding non-cash share-based compensation	13,002	1,066,016
Total assets	$ 184,027	$ 499,568